Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Vaxart, Inc.NASDAQ: VXRT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 76.8% from a year ago
Cash & equivalents stood at $50.75M at the end of Q1 FY2026, up 76.8% from a year earlier and down 5.7% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Cash & equivalents amounted to 28.2% of total assets at the end of Q1 FY2026, up 10.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +76.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 53.81M USD
- Year-over-year change
- +113.3%
- 4-year CAGR
- -21.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.81M | +113.3% |
| FY2024 | 2024-12-31 | 25.23M | -27.4% |
| FY2023 | 2023-12-31 | 34.76M | -21.0% |
| FY2022 | 2022-12-31 | 44.01M | -69.4% |
| FY2021 | 2021-12-31 | 143.75M | — |
Cash & Equivalents vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's Mar 2026 cash & equivalents of $50.75M is the 5th highest of the 10 companies compared; the peer median is $39.13M.
- Its year-over-year change of +76.8% is the 6th highest of 10, against a peer median of +89.0%.
- Cash & equivalents amounts to 28.2% of total assets for VXRT, versus a peer median of 58.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $255.84M | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $128.06M | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $99.21M | +101.1% | — | 94.1% | |
| Mar 2026 | $50.75M | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $37.37M | +89.0% | +300.4% | 58.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M | -13.0% | +12.0% | 31.6% |
CBUSCibus, Inc. | Mar 2026 | $30.33M | +28.6% | +42.5% | 9.4% |
| Mar 2026 | $9.78M | +750.3% | -13.5% | 4.2% | |
| Peer median (excluding VXRT) | $39.13M | +89.0% | -2.6% | 58.0% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 143.75M | 44.01M | 34.76M | 25.23M | 53.81M |
| Short-term Investments | 22.74M | 49.7M | 4.96M | 26.49M | 9.99M |
| Net Receivables | 71K | 20K | 3.01M | 11.97M | 51.35M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2M | 333K | 318K | 667K |
| Total Current Assets | 169.17M | 99.45M | 45.54M | 68.26M | 136.12M |
| Property, Plant & Equipment (Net) | 19.77M | 41.3M | 36.57M | 29.11M | 16.87M |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M |
| Intangible Assets | 10.62M | 5.02M | 4.29M | 3.56M | 2.83M |
| Long-term Investments | 16.21M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 890K | 3.57M | 926K | 60.96M | 25.76M |
| Total Non-current Assets | 52M | 54.4M | 46.29M | 98.13M | 49.96M |
| Total Assets | 221.17M | 153.85M | 91.83M | 166.39M | 186.08M |
| Account Payables | 3.87M | 5.51M | 1.58M | 6.96M | 21.5M |
| Short-term Debt | 836K | 95K | 3.8M | 4.06M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 13.02M |
| Other Current Liabilities | 1 | 2M | 0 | 65.4M | 5.63M |
| Total Current Liabilities | 10.78M | 17.92M | 13.72M | 90.88M | 86.75M |
| Long-term Debt | 10.69M | 5.62M | 2.62M | 1.7M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 2.02M |
| Other Non-current Liabilities | 171K | 231K | 293K | 439K | 3.5M |
| Total Non-current Liabilities | 22.85M | 25.33M | 20.3M | 16.59M | 11.53M |
| Total Liabilities | 33.64M | 43.25M | 34.03M | 107.46M | 98.28M |
| Common Stock | 13K | 13K | 15K | 23K | 24K |
| Retained Earnings | (219.35M) | (327.11M) | (409.57M) | (476.52M) | (460.2M) |
| Accumulated OCI | (74K) | (299K) | (1K) | 4K | (3K) |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 187.53M | 110.6M | 57.81M | 58.93M | 87.8M |
| Total Debt | 24.53M | 27.42M | 26.51M | 23.28M | 8.99M |
| Net Debt | (119.22M) | (16.59M) | (8.24M) | (1.95M) | (44.83M) |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.